Drugs / BK-virus specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04293042 | Oct 2019 → Jan 2028 expected | polyomavirus infectious disease | Children's Hospital of Philadelphia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BK-virus specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04293042 ↗ |
| Modality | Cell therapy | “using cytotoxic T lymphocytes (CTLs)” NCT04293042 ↗ |
| Route | Intravenous | “BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0” NCT04293042 ↗ |